Search

Displaying results 3321 - 3330 of 8010 in total
  1. Drug

    Silodosin

    go.drugbank.com/drugs/DB06207
    ApprovedInvestigational

    It is indicated for the symptomatic treatment of benign prostatic hyperplasia in adults. … to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for

  2. Drug

    Protirelin

    go.drugbank.com/drugs/DB09421
    Approved

    It is a tri-peptide tropic hormone, released by the hypothalamus, that stimulates the release of Thyroid Stimulating Hormone (TSH) and prolactin from the anterior pituitary.

    Categories: Tests for Thyreoidea Function
  3. Drug

    Azlocillin

    go.drugbank.com/drugs/DB01061
    Approved

    Azlocillin is a semisynthetic ampicillin-derived acylureido penicillin.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Morphine glucuronide

    go.drugbank.com/drugs/DB06409
    Investigational

    Categories: Heterocyclic Compounds with 4 or More Rings
  5. Drug

    Flufenamic acid

    go.drugbank.com/drugs/DB02266
    Approved

    It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)

  6. Drug

    Lecanemab

    go.drugbank.com/drugs/DB14580
    ApprovedInvestigational

    [A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.

  7. Drug

    GED-0507-34-Levo

    go.drugbank.com/drugs/DB16109
    Investigational

    GED-0507-34-Levo is under investigation in clinical trial NCT02808390 (Efficacy and Safety Study of Ged-0507-34-levo for Treatment of UC).

  8. Drug

    Lasofoxifene

    go.drugbank.com/drugs/DB06202
    ApprovedInvestigationalWithdrawn

    It was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal atrophy, in which were both rejected for approval by FDA. … It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment of vaginal atrophy.

  9. Drug

    Modafinil

    go.drugbank.com/drugs/DB00745
    ApprovedInvestigational

    Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. … The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  10. Drug

    AT3022

    go.drugbank.com/drugs/DB05172
    Experimental

    AT3022, the Altea Therapeutics’s fentanyl citrate transdermal patch designed to provide safe and rapid management of moderate to severe chronic pain.